20.4% CagriSema Trial REDEFINE 2 (NEJM 2025) Duration 68 weeks Population T2D + BMI 27 (n=1,206) Mean Weight Loss 13.7% CagriSema vs 3.4% placebo
Pegtel, D
If You Want to Start or Restart Correctly Reintroduction should be slow and deliberate
Primers (sequences in table 1) were designed using Primer 3 software and synthesized by Generi Biotech (Hradec Kralove, Czech Republic)
Optimal recovery and maintenance of results are given as post-infusion instructions
Daniela Avino, MD, neonatologist, Neonatal Intensive Care Unit, Hpital Universitaire des Enfants Reine Fabiola, Hpital Universitaire de Bruxelles, Universit libre de Bruxelles, Brussels, Belgium